Search results for: 'drug eluting b'

The coronary stent market is in the midst of tremendous change. The declining popularity of bare-metal stents have opened up opportunities for the next generation of stents to occupy the market share. This research service identifies possible areas of innovation available for stent companies to leverage and differentiate their products in a highly ...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) encompasses insights across advances in targeted neurological therapies, cancer treatments, and AI-powered drug development. The TOE also features innovators for treatment of metabolic diseases such as obesity and heart failure.The Life Science, Health & Wellnes...

12 Aug 2020  |  North America  |  Market Research

New Drug Development for Rare Pediatric Disorders Sustaining High Growth in the Global Orphan Drugs Market, 2019–2025

AI-powered Early Disease Diagnosis and Drug Repurposing will Create New Growth Opportunities

Infographics

×

Key Issues Addressed

Rare diseases have been an increasing area of focus as three waves have converged in recent years: genomic research and innovations becoming mainstream; the forthcoming regulatory policies and financial incentives put in place by the federal agencies; and the increasingly patient-centric and coordinated efforts of patient advocacy groups, caregive...

Excipients are used to support the delivery of the APIs (active pharmaceutical ingredients) through oral dosage, parenteral, and transdermal medications. For oral dosages, the key delivery forms are tablets and capsules. This research service covers the North American oral solid drug dosage excipients market. Based on functionality, excipients are ...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides insights across recent technology advances across cell & gene therapies, immunotherapies, intelligent drug discovery approaches, automated biomanufacturing and microbiome sciences. The TOE also encompasses recent developments in proteomics, drug deliver...

This Frost Radar™ analyzes the competitive landscape of the antibody-drug conjugate (ADC) contract development and manufacturing organization (CDMO) market. Companies provide the foundational manufacturing and development services for what has become one of the most dynamic and valuable therapeutic modalities in oncology. The success of the ADC rev...

Pharmaceutical companies spend billions of dollars in drug development because of expensive and time-consuming clinical trials, with a meager success rate. Frequent clinical visits, manual data processing, and a lack of consistent data on the effectiveness of the investigation of medical products contribute to their low success rate. Digital bio...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) delivers provides strategic insights into breakthrough innovations shaping the future of healthcare, life sciences, and precision therapeutics. It highlights advances in AI-enabled diagnostics, metabolic reprogramming, small molecules, deep proteomics, RNA disco...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping drug discovery, diagnostics, and therapeutic delivery across oncology, infectious diseases, rare and autoimmune disorders, metabolic and age-related conditions, neurodegenerative and neuromu...